OpGen, Curetis, and Ares Genetics have combined their businesses to build stronger diagnostic solutions for severe infections. Read more.

Rapid and comprehensive

molecular diagnostic infectious disease panels, including detection of bacterial co-infections in COVID-19 pneumonia.

A new light on antibiotic resistance

Using the power of genomics and informatics to fight antibiotic-resistant microbes

Optimizing Genomic Testing for Antibiotic Resistance

Existing tests can take days to identify the correct treatment for a patient’s infection. That’s why caregivers often use broad-spectrum antibiotics as a first defense—but when those drugs are overused, antibiotic-resistant microbes can emerge. OpGen is developing a better way to treat infection while preventing antibiotic resistance. We harness the power of informatics and genomics to identify antimicrobial resistant (AMR) organisms quickly and accurately, with an aim to improve treatment at the patient, hospital, and network level.


Deaths each year from bacterial infections (WHO)


Deaths annually in the us & europe from drug-resistant infections

$20 billion

Excess direct healthcare costs in the us from drug-resistant infections

Oliver Schacht Video


CEO Oliver Schacht discusses the new OpGen

Watch Now

Digital Trends logo

In The News

COVID-19 patients at risk for bacterial pneumonia co-infection.

Learn More

antimicrobial agents


OpGen accurately and reliably predicts antibiotic resistance in comprehensive study

Read More

Latest News

  • 8.5.20
    OpGen to Provide Business Update and Financial Results for the Second Quarter 2020  MORE
  • 7.15.20
    OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2020  MORE
  • 7.13.20
    Menarini Silicon Biosystems Partners with OpGen to Broaden Distribution of CELLSEARCH Platform in North America  MORE

See all news

Upcoming Events

  • 8.12.20
    Q2 2020 OpGen, Inc. Earnings Conference Call  MORE

See all events

Latest Blog Posts

  • 7.23.20
    New Antibiotics won’t solve the Antibiotic Resistance Crisis, but better Diagnostics could  MORE
  • 7.22.20
    Assessing the Potential of Short-Read and Long-Read Sequencing to Predict Phenotypic Antimicrobial Susceptibility Testing Results in Carbapenem-Resistant Klebsiella pneumoniae  MORE
  • 7.22.20
    Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates  MORE

See blog

Contact Us

For more information on our products and services:
  • This field is for validation purposes and should be left unchanged.